BMO Capital Markets Cuts Chemours (NYSE:CC) Price Target to $18.00

Chemours (NYSE:CC) had its price target reduced by BMO Capital Markets from $26.00 to $18.00 in a research report released on Thursday, MarketBeat.com reports. BMO Capital Markets currently has an outperform rating on the specialty chemicals company’s stock.

CC has been the subject of a number of other reports. Truist Financial reduced their price objective on shares of Chemours from $30.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Weiss Ratings downgraded Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, August 6th. Royal Bank Of Canada dropped their target price on Chemours from $26.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Zacks Research cut Chemours from a “strong-buy” rating to a “strong sell” rating in a research report on Tuesday, August 11th. Finally, Morgan Stanley set a $18.00 price target on Chemours in a research note on Monday, August 10th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.10.

Chemours Stock Performance

Shares of CC stock opened at $15.81 on Thursday. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67. The company’s fifty day simple moving average is $18.54 and its 200-day simple moving average is $20.00. The firm has a market cap of $2.38 billion, a PE ratio of -8.28 and a beta of 1.43. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98.

Chemours (NYSE:CC) last released its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period last year, the business posted ($2.54) EPS. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. Equities research analysts expect that Chemours will post 0.88 EPS for the current fiscal year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be issued a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, August 14th. Chemours’s payout ratio is currently -18.32%.

Insider Activity

In related news, CEO Denise Dignam bought 3,378 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was bought at an average price of $14.95 per share, for a total transaction of $50,501.10. Following the purchase, the chief executive officer owned 339,916 shares in the company, valued at $5,081,744.20. This represents a 1.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Calderon Gerardo Familiar bought 1,935 shares of Chemours stock in a transaction that occurred on Wednesday, August 12th. The shares were bought at an average cost of $15.53 per share, with a total value of $30,050.55. Following the acquisition, the insider directly owned 58,547 shares in the company, valued at $909,234.91. This trade represents a 3.42% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 8,663 shares of company stock valued at $130,601 over the last ninety days. 0.85% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Chemours during the second quarter worth approximately $477,769,000. Cooper Creek Partners Management LLC bought a new position in shares of Chemours during the third quarter worth approximately $63,103,000. Wolf Hill Capital Management LP bought a new position in shares of Chemours during the second quarter worth approximately $59,698,056,000. Bank of New York Mellon Corp bought a new position in shares of Chemours during the second quarter worth approximately $33,353,000. Finally, Scopia Capital Management LP lifted its holdings in Chemours by 71.7% during the 2nd quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company’s stock worth $38,418,000 after purchasing an additional 1,401,539 shares during the last quarter. 76.26% of the stock is owned by institutional investors.

Key Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours is expanding its low-GWP Opteon refrigerant portfolio to address rising cooling demand from AI-driven data centers. The initiative could support growth in a higher-demand market while aligning with customers’ decarbonization goals. Zacks article on Chemours refrigerants for data centers
• Positive Sentiment: CEO Denise Dignam bought 3,378 shares for approximately $50,500, while insider Gerardo Familiar Calderon purchased 1,935 shares for roughly $30,000. The open-market purchases may suggest that insiders view the recent share-price weakness as an opportunity. SEC filing on CEO purchase SEC filing on insider purchase
• Neutral Sentiment: BMO Capital Markets cut its price target from $26 to $18 but maintained an “outperform” rating, leaving implied upside while signaling reduced expectations. The broader analyst consensus remains “hold,” with an average target near $20.10.
• Negative Sentiment: A securities-fraud investigation involving Chemours was announced, creating a potential legal and reputational overhang for shareholders. The announcement does not establish wrongdoing, but it may increase uncertainty around the company.
• Negative Sentiment: JPMorgan lowered its price target from $22 to $15 and kept a “neutral” rating, while Zacks Research downgraded the stock from “strong buy” to “strong sell.” These actions reinforce concerns following Chemours’ recent quarterly EPS and revenue misses. Benzinga report on JPMorgan target cut Zacks rating report

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.